# Recombinant Cell-Permeable Puromycin N-Acetyltransferase Confers Puromycin Resistance by Direct Protein Transduction

**Authors:** Jiwon Choi, Kyung-Hee Cho, Jiwon Im, Yeeun Seo, Amitesh Sharma, Kartic, Shivani Devi, Nattan Stalin, Seo Jin Park, Tae-Sik Park

PMC · DOI: 10.4014/jmb.2502.02049 · Journal of Microbiology and Biotechnology · 2025-07-18

## TL;DR

This study shows that a modified PAC protein can enter mammalian cells and protect them from puromycin, offering a new method for cell selection.

## Contribution

Demonstrates that TAT-PAC protein can be delivered into cells without genetic modification, enabling puromycin resistance.

## Key findings

- TAT-PAC protein was successfully expressed and retained enzymatic activity.
- TAT-PAC delivery into cells was confirmed using confocal microscopy and flow cytometry.
- TAT-PAC conferred puromycin resistance in HEK293 and SY5Y cells.

## Abstract

Puromycin N-acetyltransferase (PAC) is an enzyme that catalyzes the acetylation of puromycin, an inhibitor of protein synthesis. The PAC gene is often co-transfected with genes of interest in the same vector to serve as a selective marker, conferring puromycin resistance to mammalian cells. Cell-penetrating peptides (CPPs), which are 5-30 amino acids in length, facilitate the translocation of functional cargoes across the cell membrane. Among these, the HIV-transactivator of transcription (TAT) sequence is widely applied for its cell-penetrating and protein-delivery capabilities. In this study, we investigated whether attachment of the TAT sequence to PAC (TAT-PAC) enables intracellular delivery of TAT-PAC protein into mammalian cells, thereby conferring puromycin resistance. A recombinant TAT-PAC protein was expressed in Escherichia coli and purified to homogeneity. The purified TAT-PAC protein retained enzymatic activity, with a specific activity of 197 nmol/min/mg. Intracellular delivery of TAT-PAC was confirmed using confocal microscopy and flow cytometry, employing an RFP (red fluorescent protein)-tagged TAT-PAC fusion protein. Treatment of HEK293 and SY5Y cells with TAT-PAC resulted in increased cell viability in the presence of puromycin, demonstrating its functionality as a selection marker. This study suggests the potential application of cell-permeable PAC protein for selection of co-delivered therapeutic or gene-editing proteins in mammalian cells, providing a promising alternative to traditional genetic selection methods.

## Linked entities

- **Genes:** PACC1 (proton activated chloride channel 1) [NCBI Gene 55248], TAT (tyrosine aminotransferase) [NCBI Gene 6898]
- **Proteins:** PACC1 (proton activated chloride channel 1), TRIM27 (tripartite motif containing 27)
- **Chemicals:** puromycin (PubChem CID 439530)
- **Species:** Escherichia coli (taxon 562)

## Full-text entities

- **Chemicals:** Puromycin (MESH:D011691)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676]
- **Cell lines:** HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), SY5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12325001/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12325001/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12325001/full.md

---
Source: https://tomesphere.com/paper/PMC12325001